(Bloomberg) -- With Europe's equities market in a particularly unforgiving mood on Thursday, the year's worst performer on the Stoxx 600 index was shown little mercy.
Shares of Indivior Plc, the London-based maker of opioid addiction treatments, dropped as much as 15 percent to a record low of 80.06 pence. That extended its drop for 2018 to almost 80 percent, equating to a 2.4 billion-pound ($3.1 billion) loss of value.
Indivior has been plagued by fears that a rival's copycat drug will end the dominance of its Suboxone film treatment. Those concerns multiplied last month when a court ruling opened the door for Dr. Reddy's Laboratories Ltd. to begin sales of a generic.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Hopes that Indivior might be able to shift patients onto its newer product, Sublocade, have also suffered a blow as prescription growth was hindered by a reimbursement model deemed unfavorable by doctors.
To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net
To contact the editors responsible for this story: Beth Mellor at bmellor@bloomberg.net, Paul Jarvis
©2018 Bloomberg L.P.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
